Limits...
Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus

The effect of OEA (A and B) (n = 6 inserts from three separate experiments), PEA (C and D) (n = 5–6 inserts from three separate experiments), virodhamine (E and F) (n = 6 inserts from three separate experiments), 2-AG (G) (n = 6 inserts from three separate experiments), oleamide (H) (n = 6 inserts from three separate experiments), NADA (I) (n = 4–5 inserts from two separate experiments) and noladin ether (J) (n = 5 inserts from three separate experiments) administered before 4 h OGD on TEER. Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05; compared with vehicle-treated inserts; Student's t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4459020&req=5

fig06: The effect of OEA (A and B) (n = 6 inserts from three separate experiments), PEA (C and D) (n = 5–6 inserts from three separate experiments), virodhamine (E and F) (n = 6 inserts from three separate experiments), 2-AG (G) (n = 6 inserts from three separate experiments), oleamide (H) (n = 6 inserts from three separate experiments), NADA (I) (n = 4–5 inserts from two separate experiments) and noladin ether (J) (n = 5 inserts from three separate experiments) administered before 4 h OGD on TEER. Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05; compared with vehicle-treated inserts; Student's t-test.

Mentions: OEA (P < 0.01, Figure 6A and B), PEA (P < 0.05, Figure 6C and D) and virodhamine (P < 0.01, Figure 6E and F) given before OGD all significantly reduced the increase in permeability induced by the OGD protocol (see AUC values Figure 6B, D and F). The effects of these compounds were mainly observed in the reperfusion period rather than the initial increase in permeability (see Figure 6A, C and E). However, 2-AG, oleamide, NADA and noladin ether had no effect on the permeability response to OGD (Figure 6G–J). In a separate experiments, the protective effect of OEA and PEA given before OGD were inhibited by the PPARα antagonist GW6471 (Figure 7).


Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE - Br. J. Pharmacol. (2015)

The effect of OEA (A and B) (n = 6 inserts from three separate experiments), PEA (C and D) (n = 5–6 inserts from three separate experiments), virodhamine (E and F) (n = 6 inserts from three separate experiments), 2-AG (G) (n = 6 inserts from three separate experiments), oleamide (H) (n = 6 inserts from three separate experiments), NADA (I) (n = 4–5 inserts from two separate experiments) and noladin ether (J) (n = 5 inserts from three separate experiments) administered before 4 h OGD on TEER. Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05; compared with vehicle-treated inserts; Student's t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4459020&req=5

fig06: The effect of OEA (A and B) (n = 6 inserts from three separate experiments), PEA (C and D) (n = 5–6 inserts from three separate experiments), virodhamine (E and F) (n = 6 inserts from three separate experiments), 2-AG (G) (n = 6 inserts from three separate experiments), oleamide (H) (n = 6 inserts from three separate experiments), NADA (I) (n = 4–5 inserts from two separate experiments) and noladin ether (J) (n = 5 inserts from three separate experiments) administered before 4 h OGD on TEER. Data are given as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05; compared with vehicle-treated inserts; Student's t-test.
Mentions: OEA (P < 0.01, Figure 6A and B), PEA (P < 0.05, Figure 6C and D) and virodhamine (P < 0.01, Figure 6E and F) given before OGD all significantly reduced the increase in permeability induced by the OGD protocol (see AUC values Figure 6B, D and F). The effects of these compounds were mainly observed in the reperfusion period rather than the initial increase in permeability (see Figure 6A, C and E). However, 2-AG, oleamide, NADA and noladin ether had no effect on the permeability response to OGD (Figure 6G–J). In a separate experiments, the protective effect of OEA and PEA given before OGD were inhibited by the PPARα antagonist GW6471 (Figure 7).

Bottom Line: Endocannabinoids alter permeability at various epithelial barriers, and cannabinoid receptors and endocannabinoid levels are elevated by stroke, with potential neuroprotective effects.Anandamide (10 μM) and oleoylethanolamide (OEA, 10 μM) decreased BBB permeability (i.e. increased resistance).The endocannabinoids may play an important modulatory role in normal BBB physiology, and also afford protection to the BBB during ischaemic stroke, through a number of target sites.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK.

No MeSH data available.


Related in: MedlinePlus